Copyright
©The Author(s) 2025.
World J Hepatol. Mar 27, 2025; 17(3): 103854
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.103854
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.103854
Figure 2 The therapeutic effects of different gut microbiota on diseases through the production of short-chain fatty acids via different pathways and their binding to GPR43, GPR41 and GPR109A receptors.
SCFA: Short-chain fatty acid. Created from BIOGDP.com[93].
- Citation: Shu JZ, Huang YH, He XH, Liu FY, Liang QQ, Yong XT, Xie YF. Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression. World J Hepatol 2025; 17(3): 103854
- URL: https://www.wjgnet.com/1948-5182/full/v17/i3/103854.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i3.103854